Invitrogen Events at IBC's Cell Line Development and Engineering Conference

Invitrogen, a provider of essential life science technologies for disease research and drug discovery, is delighted to announce PD-Direct™ its fully integrated service for customized bioprocess development, is holding three interesting events at IBC's Cell Line Development and Engineering Conference on June 25-27th, 2007, the Hilton Hotel, La Jolla, California, USA.

The Invitrogen events begin at 11.15am on Monday June 25th with a technology workshop on how to use the Genetix ClonePix^FL system for clone selection. The workshop will be led by Gregory Van Slyke, an Invitrogen PD-Direct™ Process Engineer, with many years experience, who will share hints and tips on how to get the best performance from a ClonePix^FL system.

There are an additional two Invitrogen presentations on Wednesday June 27th which will provide insights into cell line development and media optimization. The first at 10.15 am, given by Dr Florence Wu, Director of Process Development at Invitrogen PD-Direct™discusses how to engineer cells to make them resistant to high osmolality. The second presentation at 3.30 pm entitled ?reating Media that are Optimized for Specific Cell Lines' will be run by Bryan Monroe, Process Science Fellow at Invitrogen PD-Direct™ a bioprocess expert with many years' experience in major pharma companies.

Scientists that want to find out more about these exciting events should go to the article webpage. Those that wish to register to attend these events at Cell Line Development and Engineering should use the Invitrogen promotional code of B4189SPK to obtain a 25% discount on the cost of conference registration.

Laurie Donahue-Hjelle, Director, Cell Line Development for Invitrogen PD-Direct™ commented: "The Invitrogen PD-Direct™ run workshop and presentations will provide invaluable advice on selecting and producing good quality cell lines so attending these events is a must for scientists that want to save valuable development time and produce profitable biopharmaceuticals.